|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-12-16
|
|
pubmed:abstractText |
Recent publications reveal the mechanism of action of apolipoprotein A-I (apoA-I) mimetic peptides to be the remarkable binding affinity that oxidized lipids have for these peptides compared with apoA-I. There was no difference in the binding affinity of oxidized lipids or in peptide efficacy in reducing inflammation and atherosclerosis in rabbits injected with peptides synthesized from all D- or all L-amino acids. The apoA-I mimetic peptide 4F increased the formation of pre-beta high-density lipoprotein, increased cholesterol efflux, and reduced lipoprotein oxidation in vitro; it increased antioxidants and vascular repair in type 1 diabetic rats; it improved vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in a mouse model of scleroderma; it reduced renal inflammation in low-density lipoprotein receptor-null mice fed a Western diet; it reduced arthritis in a rat model; it reduced adiposity, increased adiponectin levels, and improved insulin sensitivity in obese mice; and it improved high-density lipoprotein inflammatory properties in humans with coronary heart disease.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-10974057,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-11441137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-15831812,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-17488882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-17496220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-17570869,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-17693626,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-17925450,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-18056684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-18323573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-18323574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-18337176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-18426778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-18534265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19080728-18621920
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1534-6242
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
52-7
|
|
pubmed:dateRevised |
2011-5-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19080728-Animals,
pubmed-meshheading:19080728-Anti-Inflammatory Agents,
pubmed-meshheading:19080728-Apolipoprotein A-I,
pubmed-meshheading:19080728-Arthritis,
pubmed-meshheading:19080728-Atherosclerosis,
pubmed-meshheading:19080728-Cholesterol, HDL,
pubmed-meshheading:19080728-Diabetes Mellitus,
pubmed-meshheading:19080728-Disease Models, Animal,
pubmed-meshheading:19080728-Humans,
pubmed-meshheading:19080728-Hyperlipidemias,
pubmed-meshheading:19080728-Nephritis,
pubmed-meshheading:19080728-Obesity,
pubmed-meshheading:19080728-Scleroderma, Systemic
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Apolipoprotein A-I mimetic peptides.
|
|
pubmed:affiliation |
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. bvanlent@mednet.ucla.edu
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, N.I.H., Extramural
|
